Business · 02/12/2003Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for LEXAPRO Patent Extension
Summary
The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for LEXAPRO, a human drug product, in accordance with patent extension regulations, following a submission to the Director of Patents and Trademarks at the US Department of Commerce.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →